American Oncology Network, Inc. · OTC:AONC
American Oncology Network — Investor Presentation (September 2023)
29 slides from American Oncology Network's investor presentation, Sep 29, 2023
Slide 1: Delivering Better Care Together
Delivering Better Care Together Investor Presentation September 2023
Slide 2: General Disclaimer
General This presentation is for use by prospective supporters and investors in American Oncology Network, Inc. (the “Company”) as described herein. The presentation was created for individuals to make an evaluation of the subject matter contained herein and to assist them in evaluating the Company.
Slide 3: Forward Looking Statements
This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements’’ under applicable securities laws. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “plan,” “believe,” “expect,” “anticipate
Slide 4: Today's Presenters
Today’s Presenters 4 Todd Schonherz David Gould Chief Executive Officer Chief Financial Officer Prior Experience – 31 years Prior Experience – 26 years
Slide 5: American Oncology Network ("AON") At A Glance
American Oncology Network (“AON”) At A Glance 5 AON is building one of the fastest growing networks of community oncology practices, helping deliver high-quality cancer care across the U.S. AON Headquarters AON States 54% ~200 Revenue CAGR (1) Providers 30 77 Practices Sites of Care $1.2B LTM June 2
Slide 6: Patient Story
Patient Story 6 “It’s a wonderful community-based practice and everything you need is right there,” said Cheryl. “They take you in and get your labs done; then you see the doctor and go for treatment, if needed. The pharmacy is onsite, and your next appointments are scheduled and on your calendar be
Slide 7: Investment Highlights
Investment Highlights 7 Significant Market Opportunity Technology-Enabled Platform Delivering High-Quality Cancer Care Significant Growth Potential With Proven Profitability Repeatable Model To Build Scale Highly Experienced Management Team And Expert Physician Leadership Differentiated Model Aligne
Slide 8: Oncology Is A Large, Fragmented Market
Oncology Is A Large, Fragmented Market 8 10% 14% 76% Practices employ 1-5 oncologists Nationwide Opportunity Highly Fragmented Provider Base 1) CDC – Interactive Summary Health Statistics for Adults 2021 2) Cancer Epidemiology Biomarkers & Prevention 2020; Medical care costs associated with cancer s
Slide 9: Community Oncology Plays A Critical Role In The Ecosystem
Community Oncology Plays A Critical Role In The Ecosystem 9 Key Benefits Cost of Care Personal Community oncologists take the time to get to know their patients and their unique needs Accessible Clinics are located in the communities where patients live and work High Quality & Cutting Edge Majority
Slide 10: Substantial Scale Benefits Exist In The Industry
Larger oncology platforms have numerous advantages: Improved pricing due to purchasing scale and advanced formulary Broader recruitment efforts Greater access to various constituents (payors, pharma, clinical trials, etc.) Integrated, in-house services (e.g., specialty pharmacy, pathology lab) Centr
Slide 11: AON's Fully-Integrated Model
AON’s Fully-Integrated Model 11 AON offers community oncology practices benefits of scale through an integrated care platform, while preserving local practice autonomy ✓Real Estate Ownership ✓Physician Comp Formula ✓Capital Investments ✓Research Participation Local Practice Management Practice Mgmt.
Slide 12: AON's Platform Drives Revenue Growth And Diversification
AON’s Platform Drives Revenue Growth And Diversification 12 Specialty Pharmacy Radiation Therapy & Imaging Clinical Research Laboratory & Pathology ♦ In-house AON specialty pharmacy “insources” revenue to the practice ♦ Access to >92% of oral oncolytics ♦ 80% average script capture rate ♦ Hands-on p
Slide 13: Robust Tech Platform Underpins Operations, Driving Efficiencies
Robust Tech Platform Underpins Operations, Driving Efficiencies 13 Practice Ops Pharmacy Ops Lab Ops Research Ops Substantial investments made since inception to built an integrated technology platform that ties together our clinical and operational ecosystems One platform connects patient records,
Slide 14: Compelling Value Proposition For Patients, Providers, And Payors
Compelling Value Proposition For Patients, Providers, And Payors 14 PayorsProvidersPatients >90% Avg. Annual Physician Retention Patient Satisfaction 94% ~40% Lower cost of cancer care in the community setting vs. hospitals 38% Avg. Earnings Growth After 1 Year Better Care Better Provider Experience
Slide 15: AON Delivers High-Quality Cancer Care For Patients
AON Delivers High-Quality Cancer Care For Patients 15 Patients Community Setting Access to quality providers where patients live Fully Integrated In house lab, pharmacy, and care coordination Personalized Treatment Best-in-class technology and access to the latest treatment options Holistic Care Who
Slide 16: A Differentiated Offering To Physicians
A Differentiated Offering To Physicians 16 AON Fully Independent Other Network Models Employed Model (e.g., Hospital) Operational Autonomy Purchasing Scale Integrated Pharmacy and Lab Centralized Back Office Robust Tech Platform Aligned Economic Incentives Providers
Slide 17: Business Model Aligned With Providers For Growth
Average Pre-Distribution Pool (“PDP”) Earnings Per Physician ($K) Business Model Aligned With Providers For Growth 17 $695 $959 Before AON After 1st Year ✓ New revenue streams ✓ VBC / APM revenues ✓ Improved charge capture ✓ Improved RCM performance ✓ Improved pharmacy margins ✓ Reduced practice ove
Slide 18: Delivering Better Care At Lower Cost
Delivering Better Care At Lower Cost 18 2.0% Decrease in total expenditures compared to OCM practices 12.3% Decrease in hospital admissions 9.6% Decrease in unplanned 30-day readmissions 12.0% Decrease in emergency room visits (no admission/observation stay) 13.6% Decrease in physician and ancillary
Slide 19: Model Has Driven Strong Growth
Model Has Driven Strong Growth 19 Rapid Scaling Standalone Transition Positioned for Growth Revenue Growth 2018 2019 2020 2021 2022 2023 Practices 3 11 19 23 28 31 Providers 21 93 136 186 192 208 Practices Added $67 $320 $724 $944 $1,150 54% CAGR(1) (2) 1) Based on CY19 – CY 2022 revenue CAGR 2) Una
Slide 20: Strong "Same Practice" Growth
Strong “Same Practice” Growth 20 1) Unaudited cash collections data; excludes billed revenue and other GAAP revenue adjustments 2) Adjusted CAGR based on annualized collections for each new practice in first year with AON 3) Reflects 6 months ended June 2023, annualized +30% +30% +32% Adjusted CAGR
Slide 21: Summary Financial Performance
Summary Financial Performance 21 Revenue ($mm) Adjusted EBITDA ($mm) Track record of consistent, strong growth Calendar Year Ended Trailing Twelve $320 $725 $944 $1,150 $1,217 2019 2020 2021 2022 2Q 2023 54% CAGR History of positive EBITDA and margin expansion Calendar Year Ended Trailing Twelve 66%
Slide 22: AON Has Multiple Levers For Continued, Sustained Growth
AON Has Multiple Levers For Continued, Sustained Growth 22 Drive Organic Growth Add Practices and Markets Enhance Service Offerings Expand Margins ♦ Grow ancillary services ♦ Expand existing practices ♦ Effective patient marketing ♦ Continue capital- efficient M&A ♦ Enter targeted new markets ♦ Driv
Slide 23: Led By Team With Impressive Depth And Expertise
Led By Team With Impressive Depth And Expertise 23 32 Years of Experience Mark Moch Chief Information Officer James Gilmore Chief Pharmacy & Clinical Services Officer Anthony Belott Chief Development Officer Stephen Divers Chief Medical Officer 18 Years of Experience 26 Years of Experience 20 Years
Slide 24: Investment Highlights
Investment Highlights 24 Significant Market Opportunity Technology-Enabled Platform Delivering High-Quality Cancer Care Significant Growth Potential With Proven Profitability Repeatable Model To Build Scale Highly Experienced Management Team And Expert Physician Leadership Differentiated Model Align
Slide 25: Appendix
‘American Oncology Network Appendix
Slide 26: Supplemental Financial Information
Supplemental Financial Information 26
Slide 27: Non-GAAP Reconciliations
Non-GAAP Reconciliations 27 Direct Care Margin ($000) Practice Contribution ($000)
Slide 28: Non-GAAP Reconciliations (cont.)
Non-GAAP Reconciliations (cont.) 28 Adjusted EBITDA ($000) The company includes adjusted EBITDA because it is an important measure that our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and forecast future periods. Adjusted EB
Slide 29: Risks Related to Our Business
Risks Related to Our Business • In order to execute our growth strategy, we will need to acquire oncology practices and affiliated care providers (“Network P ractices”) through AON. Our ability to grow depends upon a number of factors, including our ability to obtain referrals for cancer patient car
American Oncology Network — Investor Presentation (September 2023) on 6ix